Potency and stability of a trivalent, catalytically inactive vaccine against botulinum neurotoxin serotypes C, E and F (triCEF)

Binz, 2010, Clostridial neurotoxins: mechanism of SNARE cleavage and outlook on potential substrate specificity reengineering, Toxins, 4, 665, 10.3390/toxins2040665 Boles, 2006, Recombinant C fragment of botulinum neurotoxin B serotype (rBoNTB (HC)) immune response and protection in the rhesus monkey, Toxicon, 47, 877, 10.1016/j.toxicon.2006.02.013 Brunt, 2018, Identification of a novel new botulinum neurotoxin gene cluster in Enterococcus, FEBS Lett. 2018, 592, 310 2011, Notice of CDC's discontinuation of investigational pentavalent (ABCDE) botulinum toxoid vaccine for workers at risk for occupational exposure to botulinum toxins, MMWR (Morb. Mortal. Wkly. Rep.), 60, 1454 Clayton, 1995, Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli, Infect. Immun., 63, 2738, 10.1128/IAI.63.7.2738-2742.1995 Contreras, 2019, A neurotoxin that specifically targets Anopheles mosquitoes, Nat. Commun., 10, 2869, 10.1038/s41467-019-10732-w Hatheway, 1994, Immunogenicity of the toxins of Clostridium botulinum, 93 Johnson, 2005, Clostridium botulinum and Clostridium tetani, vol. 8, 1035 Kiyatkin, 1997, Induction of an immune response by oral administration of recombinant botulinum toxin, Infect. Immun., 65, 4586, 10.1128/IAI.65.11.4586-4591.1997 Lam, 2015, Diverse binding modes, same goal: the receptor recognition mechanism of botulinum neurotoxin, Prog. Biophys. Mol. Biol., 117, 225, 10.1016/j.pbiomolbio.2015.02.004 Mansfield, 2015, Botulinum neurotoxin homologs in non-Clostridium species, FEBS Lett. Jan 30, 589, 342, 10.1016/j.febslet.2014.12.018 Morefield, 2008, An alternative approach to combination vaccines: intradermal administration of isolated components for control of anthrax, botulism, plague and staphylococcal toxic shock, J. Immune Base Ther. Vaccine, 6, 1 Peck, 2017 Pier, 2008, Recombinant holotoxoid vaccine against botulism, Infect. Immun. 2008, 76, 437, 10.1128/IAI.00843-07 Pirazzini, 2018, Hsp90 and Thioredoxin-Thioredoxin Reductase enable the catalytic activity of Clostridial neurotoxins inside nerve terminals, Toxicon. 2018, 147, 32 Przedpelski, 2018, Enhancing toxin based vaccines against botulism, Infect. Vaccine. 1, 36, 827 Przedpelski, 2013, Enhancing the protective immune response against botulism, Infect. Immun., 81, 2638, 10.1128/IAI.00382-13 Rummel, 2009, Botulinum neurotoxins C, E and F bind gangliosides via a conserved binding site prior to stimulation-dependent uptake with botulinum neurotoxin F utilizing the three isoforms of SV2 as second receptor, J. Neurochem., 110, 1942, 10.1111/j.1471-4159.2009.06298.x Rummel, 2015, The long journey of botulinum neurotoxins into the synapse, Toxicon, 107, 9, 10.1016/j.toxicon.2015.09.009 Rusnak, 2009, Botulinum neurotoxin vaccines: past history and recent developments, Hum. Vaccine, 12, 794, 10.4161/hv.9420 Sanford, 2010, Inhalational botulism in rhesus macaques exposed to botulinum neurotoxin complex serotypes A1 and B1, Clin. Vaccine Immunol., 17, 1293, 10.1128/CVI.00080-10 Shearer, 2012, Preclinical safety assessment of recombinant botulinum vaccine A/B (rBV A/B), Vaccine. 2, 30, 1917, 10.1016/j.vaccine.2012.01.035 Smith, 2009, Botulism and vaccines for its prevention, Vaccine, 27, D33, 10.1016/j.vaccine.2009.08.059 Webb, 2013, What next for botulism vaccine development?, Expert Rev Vaccines. May, 12, 481, 10.1586/erv.13.37 Webb, 2009, Production of catalytically inactive BoNT/A1 holoprotein and comparison with BoNT/A1 subunit vaccines against toxin subtypes A1, A2, and A3, Vaccine, 16, 4490, 10.1016/j.vaccine.2009.05.030 Webb, 2017, Recombinant botulinum neurotoxin Hc subunit (BoNT Hc) and catalytically inactive Clostridium botulinum holoproteins (ciBoNT HPs) as vaccine candidates for the prevention of botulism, Toxins, 9, 269, 10.3390/toxins9090269